The global antibody discovery market, valued at USD 11.15 billion in 2025, is expected to surge to USD 35.35 billion by 2035, ...

New-onset interstitial lung disease can be detected up to 10 years after initial negative screening in patients with systemic sclerosis, with a higher mortality risk vs those without lung involvement.

Tharimmune (THAR) builds a Canton Coin digital asset treasury with $545 million raised. Read here for a detailed investment ...

The ATS/ERS 2025 statement on interstitial pneumonia classification updates the 2013 statement, with insights on secondary ...

Nasal vaccines offer convenience and another option for those wary of needles, but traditional vaccines are best for young ...

Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans to start first‑in‑human trials of ...

The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...

Find out how AI influences drug discovery, enabling earlier predictions and reducing the risks in clinical development.

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...

Deciphering the building blocks of life has long been a painstaking process, but now a quiet revolution in computing power is changing everything – with research at the University of Otago’s Faculty ...

National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple ...